论文部分内容阅读
目的:比较酮替芬与孟鲁司特联合美普清、咳喘宁、必可酮喷雾剂等治疗咳嗽变异性哮喘的临床疗效。方法:将符合病例入选标准的120例患者随机分为观察组、对照组,每组60例。两组患者均以美普清口服、咳喘宁片口服、必可酮吸入治疗为基础治疗方案。对照组同时以酮替芬(1 mg/次,2次/d)口服。观察组同时以口服孟鲁司特钠(5 mg/次,每晚顿服)口服。2组均以15周为治疗周期,治疗后评价临床疗效。结果:观察组临床控制率63.33%,总有效率95.00%,对照组临床控制率46.67%,总有效率75.00%,两组临床控制率、总有效率相比差异有统计学意义(P<0.05)。日间症状评分、夜间症状评分两组均较治疗前减少(P<0.05);但观察组下降较对照组更明显,两组差异显著(P<0.05)。一秒用力呼气容积(FEV1),FEV1百分率两组治疗前、后相比差异显著(P<0.05)。治疗后两组相比差异显著(P<0.05)。观察组副反应发生率3.33%;对照组副反应发生率10.00%。两组差异显著(P<0.05)。结论:孟鲁司特与酮替酚均对咳嗽变异性哮喘有治疗作用,孟鲁司特的治疗作用更好。
OBJECTIVE: To compare the clinical efficacy of ketotifen and montelukast combined with meprazole, kechuanning, and beckeone spray in the treatment of cough variant asthma. Methods: A total of 120 patients eligible for inclusion in the case were randomly divided into observation group and control group, 60 cases in each group. Two groups of patients were treated with mesoprofen orally, Kechuanning tablets oral, becquer ketone inhalation therapy as the basis for treatment. The control group was treated with ketotifen (1 mg / time, twice daily) orally. The observation group was orally administered with montelukast sodium (5 mg once daily). The two groups were treated with 15 weeks as the treatment period, after which the clinical efficacy was evaluated. Results: The clinical control rate and total effective rate in the observation group were 63.33% and 95.00%, respectively. The control rate in the control group was 46.67% and the total effective rate was 75.00%. There was significant difference between the two groups in clinical control rate and total effective rate (P <0.05) ). Daytime symptom scores and nighttime symptom scores were lower in both groups than before treatment (P <0.05). However, the decrease in observation group was more obvious than that in control group (P <0.05). One second forced expiratory volume (FEV1), FEV1 percentage two groups before and after treatment was significantly different (P <0.05). After treatment, there was significant difference between the two groups (P <0.05). The incidence of adverse reactions in the observation group was 3.33%; the incidence of side effects in the control group was 10.00%. The difference between the two groups was significant (P <0.05). CONCLUSION: Both montelukast and ketotitol have a therapeutic effect on cough variant asthma, and montelukast has a better therapeutic effect.